MedTrace Logo

Beta-glucan and Immune Response to Influenza Vaccine

NCT05074303 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2025-11-06

Study results available
· View outcomes & findings →

Summary

This trial in healthy adults will determine the effects of beta-glucan, a dietary fiber supplement isolated from baker's yeast, on immune response to the influenza vaccine.

Conditions

  • Healthy Aging

Interventions

BIOLOGICAL

Influenza Vaccine

All subjects will receive the influenza vaccine.

DIETARY_SUPPLEMENT

Beta-glucan

2 - 250 mg capsules/day of beta-glucan derived from Baker's yeast

DIETARY_SUPPLEMENT

Placebo

2 - 250 mg capsules/day of cellulose

Sponsors & Collaborators

  • Danstar Ferment AG

    collaborator UNKNOWN

  • University of Florida

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-07-18
Primary Completion
2024-03-01
Completion
2024-08-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05074303 on ClinicalTrials.gov